Top Markets
#1 Siren Siren +38.43%
#2 RedStone RedStone +23.87%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +22.65%
#4 Ocean Protocol Ocean Protocol +15.39%
#5 Cysic Cysic +14.92%
#6 Arowana Arowana +13.88%
#7 Verus Coin Verus Coin +13.51%
#8 Perle Perle +11.75%
#9 KUB Coin KUB Coin +11.63%
#10 Wiki Cat Wiki Cat +10.25%
Coin of the day
Siren Siren
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Intensity Therapeutics, Inc. Intensity Therapeutics, Inc.

Intensity Therapeutics, Inc.

INTS
Classifica tra le azioni #32095
Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical... Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical development phase, dedicated to discovering, advancing, and commercializing pharmaceutical treatments for solid tumor cancers. The company's primary experimental compound, INT230-6, is presently undergoing Phase 2 clinical trials. This investigational drug targets a range of difficult-to-treat solid tumors, including those affecting the pancreas, colon, bile duct, as well as squamous cell, sarcoma, breast, and liver cancers. Intensity Therapeutics has formed strategic collaborations with major pharmaceutical companies and research institutions: A partnership with Merck Sharpe & Dohme Corp. focuses on evaluating INT230-6 in conjunction with Keytruda for advanced pancreatic, colon, squamous cell, and bile duct malignancies. Another collaboration with Bristol-Myers Squibb Company is dedicated to studying INT230-6 combined with Yervoy in patients suffering from advanced liver, breast, and sarcoma cancers. Furthermore, the company is working with the Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research on a randomized controlled Phase II neoadjuvant study of INT230-6 for women diagnosed with early-stage breast cancer. Established in 2012, Intensity Therapeutics maintains its corporate headquarters in Westport, Connecticut.
Prezzo delle azioni
$4.12
Ultima sincronizzazione: 2026-08-17
Capitalizzazione di mercato
$11.14M
Variazione (1 giorno)
4.04%
Variazione (1 anno)
-45.79%
Paese
US
Scambia Intensity Therapeutics, Inc. (INTS)

Categoria

Healthcare
Utile per Intensity Therapeutics, Inc. (INTS)
Utile nel 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Intensity Therapeutics, Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, uguale a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Intensity Therapeutics, Inc. dal 2026 al 2026
Utile alla fine di ogni anno
Anno Utile Cambia
Non abbastanza dati per le date fornite.
Utile per aziende simili o concorrenti
Azienda Utile Differenza negli utili Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR